List of works - Graziano Pelli

Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome.

scientific article published on 25 January 2011

Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability

Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4

article published in 2015

Endothelial Cx40 limits myocardial ischaemia/reperfusion injury in mice

scientific article published on 17 March 2014

Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways.

scientific article published on 21 October 2014

Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction

scientific article published on 14 May 2012

Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice

scientific article published on 7 November 2013

Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis

scientific article

Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability.

scientific article published on 24 November 2011

Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.

scientific article

Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke

scientific article

The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques.

scientific article

Treatment with Angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques

scientific article published on 06 February 2014

Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis

scientific article

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

scientific article published on 19 December 2012

Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response

scientific article published on 25 April 2015

Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice

scientific article

List of works by Graziano Pelli

Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome.

Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability

Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4

Endothelial Cx40 limits myocardial ischaemia/reperfusion injury in mice

Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways.

Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction

Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice

Pannexin1 links lymphatic function to lipid metabolism and atherosclerosis

Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability.

Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.

Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke

The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques.

Treatment with Angiotensin-(1–7) reduces inflammation in carotid atherosclerotic plaques

Treatment with Evasin-3 abrogates neutrophil-mediated inflammation in mouse acute pancreatitis

Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice

Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response

Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice